QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 FOR THE QUARTERLY PERIOD ENDED
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____________ TO
_____________
|
(Exact name of registrant as specified in its charter)
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(IRS Employer Identification No.)
|
|
||
(Address of principal executive offices, including zip code)
|
(
|
||
(Registrant’s telephone number, including area code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
|
Accelerated filer ☐
|
Non-accelerated filer ☐
|
Smaller reporting company
|
Emerging growth company
|
Page
|
|||
Part I.
|
Financial Information
|
||
Item 1.
|
Financial Statements (Unaudited):
|
||
1
|
|||
2
|
|||
3
|
|||
4
|
|||
5 | |||
6 | |||
Item 2.
|
18 | ||
Item 3.
|
27 | ||
Item 4.
|
27 | ||
Part II.
|
Other Information
|
||
Item 1.
|
28 | ||
Item 1A.
|
28 | ||
Item 2.
|
28 | ||
Item 3.
|
28 | ||
Item 4.
|
28 | ||
Item 5.
|
28 | ||
Item 6.
|
29
|
||
30 |
March 31,
2024
|
December 31,
2023
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
|
$
|
|
||||
Current investments
|
|
|
||||||
Accounts receivable, net
|
|
|
||||||
Inventories, net
|
|
|
||||||
Prepaid expenses and other
|
|
|
||||||
Total current assets
|
|
|
||||||
Property and equipment, net
|
|
|
||||||
Operating lease right-of-use assets
|
|
|
||||||
Goodwill
|
|
|
||||||
Other intangible assets, net
|
|
|
||||||
Other assets
|
|
|
||||||
Total assets
|
$
|
|
$
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
|
$
|
|
||||
Accrued expenses
|
|
|
||||||
Current portion of long-term debt
|
|
|
||||||
Total current liabilities
|
|
|
||||||
Operating lease liabilities
|
|
|
||||||
Long-term debt
|
|
|
||||||
Other liabilities
|
|
|
||||||
Total liabilities
|
|
|
||||||
Commitments and contingencies (Notes 5 and 11)
|
|
|
||||||
Stockholders’ equity:
|
||||||||
Class A common stock –
|
|
|
||||||
Additional paid-in capital
|
|
|
||||||
Treasury stock, at cost –
|
(
|
)
|
(
|
)
|
||||
Accumulated other comprehensive loss
|
(
|
)
|
(
|
)
|
||||
Retained earnings
|
|
|
||||||
Total stockholders’ equity
|
|
|
||||||
Total liabilities and stockholders’
equity
|
$
|
|
$
|
|
Three Months Ended
March 31,
|
||||||||
2024
|
2023
|
|||||||
Revenue
|
$
|
|
$
|
|
||||
Cost of sales
|
|
|
||||||
Gross profit
|
|
|
||||||
Operating expenses:
|
||||||||
Selling expenses
|
|
|
||||||
General and administrative expenses
|
|
|
||||||
Restructuring and impairment expenses |
||||||||
Total operating expenses
|
|
|
||||||
Operating income
|
|
|
||||||
Interest expense |
||||||||
Other income (expense), net
|
(
|
)
|
|
|||||
Income before provision for income taxes
|
|
|
||||||
Provision for income taxes
|
|
|
||||||
Net (loss) income
|
$
|
(
|
)
|
$
|
|
|||
Net (loss) income per share (Note 6):
|
||||||||
Basic
|
$
|
(
|
)
|
$
|
|
|||
Diluted
|
$
|
(
|
)
|
$
|
|
|||
Weighted-average common shares outstanding (000s):
|
||||||||
Basic
|
|
|
||||||
Diluted
|
|
|
Three Months Ended
March 31,
|
||||||||
2024
|
2023
|
|||||||
Net (loss) income
|
$
|
(
|
)
|
$
|
|
|||
Other comprehensive (loss) income, net of tax:
|
||||||||
Foreign currency translation adjustment, net of taxes of $
|
(
|
)
|
(
|
)
|
||||
Net unrealized gains/(losses) on cash flow hedges, net of taxes of $(
|
|
(
|
)
|
|||||
Reclassification adjustment for realized losses/(gains) in current earnings, net of taxes of
$
|
(
|
)
|
(
|
)
|
||||
(
|
)
|
(
|
)
|
|||||
Comprehensive (loss) income
|
$
|
(
|
)
|
$
|
|
For the Three Months Ended March 31, 2024
|
||||||||||||||||||||||||
Class A
Common
Stock
|
Additional
Paid-in
Capital
|
Treasury
Stock
|
Accumulated
Other
Comprehensive
Loss
|
Retained
Earnings
|
Total
|
|||||||||||||||||||
Balance at January 1, 2024
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
||||||||||
Net loss
|
|
|
|
|
(
|
)
|
(
|
)
|
||||||||||||||||
Other comprehensive loss, net of tax
|
|
|
|
(
|
)
|
|
(
|
)
|
||||||||||||||||
Exercise of employee stock options (
|
|
(
|
)
|
|
|
|
(
|
)
|
||||||||||||||||
Stock-based compensation
|
|
|
|
|
|
|
||||||||||||||||||
Cash dividends
|
|
|
|
|
(
|
)
|
(
|
)
|
||||||||||||||||
Balance at March 31, 2024
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
For the Three Months Ended March 31, 2023
|
||||||||||||||||||||||||
Class A
Common
Stock
|
Additional
Paid-in
Capital
|
Treasury
Stock
|
Accumulated
Other
Comprehensive
Loss
|
Retained
Earnings
|
Total
|
|||||||||||||||||||
Balance at January 1, 2023
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
||||||||||
Net income
|
|
|
|
|
|
|
||||||||||||||||||
Other comprehensive loss, net of tax
|
|
|
|
(
|
)
|
|
(
|
)
|
||||||||||||||||
Exercise of employee stock options (
|
|
(
|
)
|
|
|
|
|
|||||||||||||||||
Stock-based compensation
|
|
|
|
|
|
|
||||||||||||||||||
Cash dividends
|
|
|
|
|
(
|
)
|
(
|
)
|
||||||||||||||||
Balance at March 31, 2023
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
Three
Months Ended
March 31,
|
||||||||
2024
|
2023
|
|||||||
Cash flows from operating activities:
|
||||||||
Net (loss) income
|
$
|
(
|
)
|
$
|
|
|||
Adjustments to reconcile net (loss) income to cash flows from operating activities:
|
||||||||
Depreciation and amortization
|
|
|
||||||
Non-cash lease expense
|
|
|
||||||
Stock-based compensation
|
|
|
||||||
Inventory write-down
|
||||||||
Foreign currency losses / (gains)
|
|
(
|
)
|
|||||
Loss / (gain) on disposal of assets
|
|
(
|
)
|
|||||
Deferred taxes
|
|
(
|
)
|
|||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable, net
|
|
(
|
)
|
|||||
Inventories, net
|
|
(
|
)
|
|||||
Prepaid expenses and other
|
(
|
)
|
(
|
)
|
||||
Other assets
|
(
|
)
|
(
|
)
|
||||
Accounts payable
|
(
|
)
|
(
|
)
|
||||
Accrued expenses
|
(
|
)
|
(
|
)
|
||||
Other liabilities
|
(
|
)
|
(
|
)
|
||||
Net cash provided by / (used in) operating activities
|
|
(
|
)
|
|||||
Cash flows from investing activities:
|
||||||||
Purchases of property and equipment
|
(
|
)
|
(
|
)
|
||||
Proceeds on investment sales
|
|
|
||||||
Purchases of investments
|
|
(
|
)
|
|||||
Net cash used in investing activities
|
(
|
)
|
(
|
)
|
||||
Cash flows from financing activities:
|
||||||||
Exercise of employee stock options and taxes paid related to the net shares settlement of stock
awards
|
(
|
)
|
|
|||||
Payment of cash dividends
|
(
|
)
|
(
|
)
|
||||
Finance lease principal payments
|
(
|
)
|
(
|
)
|
||||
Contingent consideration payments
|
( |
) | ||||||
Payments of debt
|
(
|
)
|
(
|
)
|
||||
Proceeds from debt
|
|
|
||||||
Net cash (used in) / provided by financing activities
|
(
|
)
|
|
|||||
Effect of exchange rate changes on cash
|
(
|
)
|
|
|||||
Net decrease in cash and cash equivalents
|
(
|
)
|
(
|
)
|
||||
Cash and cash equivalents, beginning of period
|
|
|
||||||
Cash and cash equivalents, end of period
|
$
|
|
$
|
|
1. |
The Company
|
2. |
Summary of Significant Accounting Policies
|
March 31,
2024
|
December 31,
2023
|
|||||||
Raw materials
|
$
|
|
$
|
|
||||
Finished goods
|
|
|
||||||
Total Inventory, net
|
$
|
|
$
|
|
Three Months Ended
March 31,
|
||||||||
2024
|
2023
|
|||||||
Beginning balance
|
$
|
|
$
|
|
||||
Additions
|
|
|
||||||
Write-offs
|
(
|
)
|
(
|
)
|
||||
Ending Balance
|
$
|
|
$
|
|
3. |
Goodwill
|
March 31,
2024
|
December 31,
2023
|
|||||||
Nu Skin
|
||||||||
Americas
|
$
|
|
$
|
|
||||
Mainland China
|
|
|
||||||
Southeast Asia/Pacific
|
|
|
||||||
Japan
|
|
|
||||||
Europe & Africa
|
|
|
||||||
South Korea
|
||||||||
Hong Kong/Taiwan
|
|
|
||||||
Rhyz Investments
|
||||||||
Manufacturing
|
|
|
||||||
Rhyz other
|
|
|
||||||
Total
|
$
|
|
$
|
|
4. |
Debt
|
Facility or
Arrangement
|
Original
Principal
Amount
|
Balance as of
March 31,
2024(1)(2)
|
Balance as of
December 31,
2023(1)(2)
|
Interest
Rate
|
Repayment
Terms
|
|||||
Credit Agreement term loan facility
|
$
|
$
|
$
|
|
|
|||||
Credit Agreement revolving credit facility
|
$
|
$
|
|
|
(1) |
|
(2) |
|
5. |
Leases
|
Three Months Ended
March 31,
|
||||||||
2024
|
2023
|
|||||||
Operating lease expense
|
||||||||
Operating lease cost
|
$
|
|
$
|
|
||||
Variable lease cost
|
|
|
||||||
Finance lease expense
|
||||||||
Amortization of right-of-use assets
|
|
|
||||||
Interest on lease liabilities
|
|
|
||||||
Total lease
expense
|
$
|
|
$
|
|
Three
Months Ended
March 31,
|
||||||||
2024
|
2023
|
|||||||
Operating cash outflow from operating leases
|
$
|
|
$
|
|
||||
Operating cash outflow from finance leases
|
$
|
|
$
|
|
||||
Financing cash outflow from finance leases
|
$
|
|
$
|
|
||||
Right-of-use assets obtained in exchange for operating lease obligations
|
$
|
|
$
|
|
||||
Right-of-use assets obtained in exchange for finance lease obligations
|
$
|
|
$
|
|
Year Ending December 31
|
Operating
Leases
|
Finance
Leases
|
||||||
2024
|
$
|
|
$
|
|
||||
2025
|
|
|
||||||
2026
|
|
|
||||||
2027
|
|
|
||||||
2028
|
|
|
||||||
Thereafter
|
|
|
||||||
Total
|
|
|
||||||
Less: Finance charges
|
|
|
||||||
Total principal liability
|
$
|
|
$
|
|
6. |
Capital Stock
|
7. |
Fair Value and Equity Investments
|
■ |
Level 1 – quoted prices in active markets for identical assets or liabilities;
|
■ |
Level 2 – inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
|
■ |
Level 3 – unobservable inputs based on the Company’s own assumptions.
|
Fair Value at March 31,
2024
|
||||||||||||||||
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
Financial assets (liabilities):
|
||||||||||||||||
Cash equivalents and current investments
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Derivative financial instruments asset
|
|
|
|
|
||||||||||||
Life insurance contracts
|
|
|
|
|
||||||||||||
Contingent consideration
|
|
|
|
|
||||||||||||
Total
|
$
|
|
$
|
|
$
|
|
$
|
|
Fair Value at December 31, 2023
|
||||||||||||||||
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
Financial assets (liabilities):
|
||||||||||||||||
Cash equivalents and current investments
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Derivative financial instruments asset
|
|
|
|
|
||||||||||||
Life insurance contracts
|
|
|
|
|
||||||||||||
Contingent consideration
|
|
|
(
|
)
|
(
|
)
|
||||||||||
Total
|
$
|
|
$
|
|
$
|
|
$
|
|
2024
|
2023
|
|||||||
Beginning balance at January 1
|
$
|
|
$
|
|
||||
Actual return on plan assets
|
|
|
||||||
Ending balance at March 31
|
$
|
|
$
|
|
2024
|
2023
|
|||||||
Beginning balance at January 1
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Changes in fair value of contingent consideration
|
|
|
||||||
Payments
|
||||||||
Ending balance at March 31
|
$
|
|
$
|
(
|
)
|
8. |
Income Taxes
|
9. |
Derivatives and Hedging Activities
|
Fair Values of
Derivative Instruments
|
||||||||||
Derivatives in Cash flow
Hedging Relationships:
|
Balance Sheet
Location
|
March 31,
2024
|
December 31,
2023
|
|||||||
Interest Rate Swap - Asset
|
Prepaid expenses and other
|
$
|
|
$
|
|
|||||
Interest Rate Swap - Asset
|
Other assets
|
$
|
|
$
|
|
Amount of Gain (Loss)
Recognized in OCI on Derivatives
|
|||||||||
Three Months Ended
|
|||||||||
Derivatives in Cash flow
|
March 31,
|
||||||||
Hedging Relationships:
|
2024
|
2023
|
|||||||
Interest Rate Swaps
|
$
|
|
$
|
(
|
)
|
Amount of Gain
Reclassified from Accumulated
Other Comprehensive Loss into Income
|
||||||||||
Three Months Ended
|
||||||||||
Derivatives in Cash flow
|
Income Statement
|
March 31,
|
||||||||
Hedging Relationships:
|
Location
|
2024
|
2023
|
|||||||
Interest Rate Swaps
|
Other income (expense), net
|
$
|
|
$
|
|
10. |
Segment Information
|
Three Months Ended
March 31,
|
||||||||
(U.S. dollars in thousands)
|
2024
|
2023
|
||||||
Nu Skin
|
||||||||
Americas
|
$
|
|
$
|
|
||||
Mainland China
|
||||||||
Southeast Asia/Pacific
|
||||||||
Japan
|
||||||||
Europe & Africa
|
||||||||
South Korea
|
|
|||||||
Hong Kong/Taiwan
|
|
|
||||||
Other
|
|
(
|
)
|
|||||
Total Nu Skin
|
|
|
||||||
Rhyz Investments
|
||||||||
Manufacturing (1)
|
|
|
||||||
Rhyz other
|
|
|
||||||
Total Rhyz Investments
|
||||||||
Total
|
$
|
|
$
|
|
(1) |
|
Three Months Ended
March 31,
|
||||||||
(U.S.
dollars in thousands)
|
2024
|
2023
|
||||||
Nu
Skin
|
||||||||
Americas
|
$
|
|
$
|
|
||||
Mainland China
|
||||||||
Southeast Asia/Pacific
|
||||||||
Japan
|
||||||||
Europe & Africa
|
|
|
||||||
South Korea
|
||||||||
Hong
Kong/Taiwan
|
|
|
||||||
Nu Skin
contribution
|
|
|
||||||
Rhyz
Investments
|
||||||||
Manufacturing
|
|
(
|
)
|
|||||
Rhyz other
|
( |
) | ( |
) | ||||
Total Rhyz Investments
|
( |
) | ( |
) | ||||
Total
segment contribution
|
|
|
||||||
Corporate
and other
|
(
|
)
|
(
|
)
|
||||
Operating
income
|
|
|
||||||
Interest expense | ||||||||
Other
income (expense), net
|
(
|
)
|
|
|||||
Income
before provision for income taxes
|
$
|
|
$
|
|
Three Months Ended
March 31,
|
||||||||
(U.S. dollars in thousands)
|
2024
|
2023
|
||||||
Nu Skin
|
||||||||
Americas
|
$
|
|
$
|
|
||||
Mainland China
|
||||||||
Southeast Asia/Pacific
|
||||||||
Japan
|
||||||||
Europe & Africa
|
|
|
||||||
South Korea
|
||||||||
Hong Kong/Taiwan
|
|
|
||||||
Total Nu Skin
|
|
|
||||||
Rhyz Investments
|
||||||||
Manufacturing
|
|
|
||||||
Rhyz other
|
|
|
||||||
Total Rhyz Investments
|
||||||||
Corporate and other
|
|
|
||||||
Total
|
$
|
|
$
|
|
Three Months Ended
March 31,
|
||||||||
(U.S. dollars in thousands)
|
2024
|
2023
|
||||||
Nu Skin
|
||||||||
Americas
|
$
|
|
$
|
|
||||
Mainland China
|
||||||||
Southeast Asia/Pacific
|
||||||||
Japan
|
||||||||
Europe & Africa
|
|
|||||||
South Korea
|
||||||||
Hong Kong/Taiwan
|
|
|
||||||
Total Nu Skin
|
|
|
||||||
Rhyz Investments
|
||||||||
Manufacturing
|
|
|
||||||
Rhyz other
|
||||||||
Total Rhyz Investments
|
||||||||
Corporate and other
|
|
|
||||||
Total
|
$
|
|
$
|
|
11. |
Commitments and Contingencies
|
12. |
Acquisitions
|
13. |
Restructuring
|
(U.S. dollars in thousands)
|
Three Months Ended
March 31, 2023
|
Year Ended
December 31, 2022
|
Total |
|||||||||
Nu Skin
|
||||||||||||
Americas
|
$
|
|
$ |
$ |
||||||||
Mainland China
|
||||||||||||
Southeast Asia/Pacific
|
|
|||||||||||
Japan
|
|
|||||||||||
Europe & Africa
|
(
|
)
|
||||||||||
South Korea
|
|
|||||||||||
Hong Kong/Taiwan
|
(
|
)
|
||||||||||
Total Nu Skin
|
|
|||||||||||
Rhyz Investments
|
||||||||||||
Manufacturing
|
|
|||||||||||
Rhyz other
|
|
|||||||||||
Total Rhyz Investments
|
|
|||||||||||
Corporate and other
|
|
|||||||||||
Total
|
$
|
|
$ |
$ |
Three Months Ended
|
||||||||||||
(U.S. dollars in thousands)
|
March 31,
2024
|
December 31,
2023
|
Total
|
|||||||||
Nu Skin
|
||||||||||||
Americas
|
$
|
|
$
|
|
$
|
|
||||||
Mainland China
|
|
|
|
|||||||||
Southeast Asia/Pacific
|
|
|
|
|||||||||
Japan
|
|
|
|
|||||||||
Europe & Africa
|
|
|
|
|||||||||
South Korea
|
|
|
|
|||||||||
Hong Kong/Taiwan
|
|
|
|
|||||||||
Total Nu Skin
|
|
|
|
|||||||||
Rhyz Investments
|
||||||||||||
Manufacturing
|
|
|
|
|||||||||
Rhyz other
|
|
|
|
|||||||||
Total Rhyz Investments
|
|
|
|
|||||||||
Corporate and other
|
|
|
|
|||||||||
Total
|
$
|
|
$
|
|
$
|
|
ITEM 2. |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
Three Months Ended
March 31,
|
Constant-
Currency
|
|||||||||||||||
2024
|
2023
|
Change
|
Change(1)
|
|||||||||||||
Nu Skin
|
||||||||||||||||
Americas
|
$
|
75,031
|
$
|
101,157
|
(25.8
|
)%
|
(20.1
|
)%
|
||||||||
Mainland China
|
61,067
|
67,976
|
(10.2
|
)%
|
(6.1
|
)%
|
||||||||||
Southeast Asia/Pacific
|
60,065
|
67,810
|
(11.4
|
)%
|
(8.1
|
)%
|
||||||||||
Japan
|
44,236
|
52,606
|
(15.9
|
)%
|
(5.6
|
)%
|
||||||||||
Europe & Africa
|
42,273
|
47,444
|
(10.9
|
)%
|
(11.8
|
)%
|
||||||||||
South Korea
|
40,963
|
70,324
|
(41.8
|
)%
|
(39.3
|
)%
|
||||||||||
Hong Kong/Taiwan
|
30,466
|
34,548
|
(11.8
|
)%
|
(9.8
|
)%
|
||||||||||
Other
|
672
|
(115
|
)
|
684.3
|
%
|
684.3
|
%
|
|||||||||
Total Nu Skin
|
354,773
|
441,750
|
(19.7
|
)%
|
(15.6
|
)%
|
||||||||||
Rhyz Investments
|
||||||||||||||||
Manufacturing
|
50,302
|
35,767
|
40.6
|
%
|
40.6
|
%
|
||||||||||
Rhyz other
|
12,231
|
3,945
|
210.0
|
%
|
210.0
|
%
|
||||||||||
Total Rhyz Investments
|
62,533
|
39,712
|
57.5
|
%
|
57.5
|
%
|
||||||||||
Total
|
$
|
417,306
|
$
|
481,462
|
(13.3
|
)%
|
(9.5
|
)%
|
(1) |
Constant-currency revenue change is a non-GAAP financial measure. See “Non-GAAP Financial Measures,” below.
|
Three Months Ended
March 31,
|
||||||||||||
2024
|
2023
|
Change
|
||||||||||
Nu Skin
|
||||||||||||
Americas
|
$
|
14,976
|
$
|
16,250
|
(7.8
|
)%
|
||||||
Mainland China
|
12,253
|
13,612
|
(10.0
|
)%
|
||||||||
Southeast Asia/Pacific
|
11,084
|
12,471
|
(11.1
|
)%
|
||||||||
Japan
|
12,006
|
12,908
|
(7.0
|
)%
|
||||||||
Europe & Africa
|
3,276
|
3,638
|
(10.0
|
)%
|
||||||||
South Korea
|
12,183
|
23,575
|
(48.3
|
)%
|
||||||||
Hong Kong/Taiwan
|
7,367
|
7,834
|
(6.0
|
)%
|
||||||||
Total Nu Skin
|
73,145
|
90,288
|
(19.0
|
)%
|
||||||||
Rhyz Investments
|
||||||||||||
Manufacturing
|
1,967
|
(1,373
|
)
|
243.3
|
%
|
|||||||
Rhyz other
|
(5,942
|
)
|
(1,960
|
)
|
(203.2
|
)%
|
||||||
Total Rhyz Investments
|
(3,975
|
)
|
(3,333
|
)
|
(19.3
|
)%
|
● |
“Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and
those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.
|
● |
“Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our
independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.
|
● |
“Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the
quarter.
|
Three Months Ended
March 31,
|
||||||||||||
2024
|
2023
|
Change
|
||||||||||
Customers
|
||||||||||||
Americas
|
199,399
|
266,378
|
(25
|
)%
|
||||||||
Mainland China
|
162,239
|
217,101
|
(25
|
)%
|
||||||||
Southeast Asia/Pacific
|
93,411
|
117,266
|
(20
|
)%
|
||||||||
Japan
|
108,808
|
115,161
|
(6
|
)%
|
||||||||
Europe & Africa
|
163,481
|
190,313
|
(14
|
)%
|
||||||||
South Korea
|
100,230
|
120,907
|
(17
|
)%
|
||||||||
Hong Kong/Taiwan
|
47,693
|
56,410
|
(15
|
)%
|
||||||||
Total Customers
|
875,261
|
1,083,536
|
(19
|
)%
|
||||||||
Paid Affiliates
|
||||||||||||
Americas
|
29,081
|
38,707
|
(25
|
)%
|
||||||||
Mainland China
|
24,405
|
24,522
|
—
|
|||||||||
Southeast Asia/Pacific
|
29,778
|
36,431
|
(18
|
)%
|
||||||||
Japan(1)
|
21,679
|
37,155
|
(42
|
)%
|
||||||||
Europe & Africa(1)
|
18,313
|
27,654
|
(34
|
)%
|
||||||||
South Korea(1)
|
20,594
|
40,599
|
(49
|
)%
|
||||||||
Hong Kong/Taiwan(1)
|
10,321
|
16,286
|
(37
|
)%
|
||||||||
Total Paid Affiliates
|
154,171
|
221,354
|
(30
|
)%
|
||||||||
Sales Leaders
|
||||||||||||
Americas
|
6,616
|
8,242
|
(20
|
)%
|
||||||||
Mainland China
|
9,600
|
10,034
|
(4
|
)%
|
||||||||
Southeast Asia/Pacific
|
5,570
|
6,337
|
(12
|
)%
|
||||||||
Japan
|
6,385
|
5,688
|
12
|
%
|
||||||||
Europe & Africa
|
3,715
|
4,524
|
(18
|
)%
|
||||||||
South Korea
|
4,122
|
6,242
|
(34
|
)%
|
||||||||
Hong Kong/Taiwan
|
2,601
|
2,688
|
(3
|
)%
|
||||||||
Total Sales Leaders
|
38,609
|
43,755
|
(12
|
)%
|
(1) |
The March 31, 2024 number is affected by a change in eligibility requirements for receiving certain rewards within our compensation structure, to more narrowly focus on those affiliates who are actively building a consumer base. See
“Japan,” “Europe & Africa,” “South Korea,” and “Hong Kong/Taiwan,” below. We plan to implement these changes in additional segments over the next several quarters.
|
● |
Rhyz plant expansion to increase capacity and capabilities;
|
● |
purchases and expenditures for computer systems and equipment, software, and application development; and
|
● |
the expansion and upgrade of facilities in our various markets.
|
● |
Financial projections and future cash flows, including a base year that considered recent actual results lower than previous internal forecasts, with revenue growth and profitability improvement throughout the forecast period that
reflects the long-term strategy for the business, and terminal growth rates based on the expected long-term growth rate of the business; and
|
● |
Market-based discount rates.
|
ITEM 3. |
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
ITEM 4. |
CONTROLS AND PROCEDURES
|
ITEM 1. |
LEGAL PROCEEDINGS
|
ITEM 1A. |
RISK FACTORS
|
ITEM 2. |
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
|
(a)
|
(b)
|
(c)
|
(d)
|
|||||||||||||
Period
|
Total
Number
of Shares
Purchased
|
Average
Price Paid
per Share
|
Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs
|
Approximate Dollar
Value of Shares that May
Yet Be Purchased Under
the Plans or Programs
(in millions)(1)
|
||||||||||||
January 1 - 31, 2024
|
—
|
$
|
—
|
—
|
$
|
162.4
|
||||||||||
February 1 - 29, 2024
|
—
|
—
|
—
|
$
|
162.4
|
|||||||||||
March 1 -31, 2024
|
—
|
—
|
—
|
$
|
162.4
|
|||||||||||
Total
|
—
|
$
|
—
|
—
|
(1) |
In August 2018, we announced that our board of directors approved a stock repurchase plan. Under this plan, our board of directors authorized the repurchase of up to $500 million of our outstanding Class A common stock on the open market
or in privately negotiated transactions.
|
ITEM 3. |
DEFAULTS UPON SENIOR SECURITIES
|
ITEM 4. |
MINE SAFETY DISCLOSURES
|
ITEM 5. |
OTHER INFORMATION
|
ITEM 6. |
EXHIBITS
|
Exhibits
Regulation S-K
Number
|
Description
|
|
Fifth Amended and Restated Bylaws of Nu Skin Enterprises, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K
filed February 6, 2024).
|
||
Consulting Agreement between the Company and Joseph Y. Chang, effective as of March 30, 2024.
|
||
Certification by Ryan S. Napierski, Chief Executive Officer, pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002.
|
||
Certification by James D. Thomas, Chief Financial Officer, pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002.
|
||
Certification by Ryan S. Napierski, Chief Executive Officer, pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
||
Certification by James D. Thomas, Chief Financial Officer, pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
||
101.INS
|
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the
Inline XBRL document)
|
|
101.SCH
|
Inline XBRL Taxonomy Extension Schema Document
|
|
101.CAL
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF
|
Inline XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB
|
Inline XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document
|
|
104
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
|
NU SKIN ENTERPRISES, INC.
|
||
By:
|
/s/ James D. Thomas
|
|
James D. Thomas
|
||
Chief Financial Officer
|
||
(Duly Authorized Officer and Principal Financial Officer)
|
A.
|
Prior to the termination of Consultant’s employment, Consultant served as an Executive of the Company, pursuant to an employment agreement dated October 15, 2020 (the “Employment Agreement”).
|
B.
|
The Company desires to obtain certain rights related to Consultant and to retain Consultant as an independent contractor to provide certain consulting services to the Company.
|
C.
|
The Consultant is willing to grant such rights and provide such services pursuant to the terms and conditions set forth in this Agreement.
|
a.
|
Consulting services up to 10 hours per month;
|
b.
|
Service as a member (and Chairman as long as such role is mutually agreeable) of the Company’s Scientific Advisory Board (the standard duties of members of such Board are set forth in Exhibit A);
|
c.
|
Appearances and speaking engagements up to 10 days per year that comply with the Company’s approved product claims and scripts; and
|
d.
|
Full rights and authorization to use Consultant’s name and likeness for the Company’s marketing and other purposes.
|
If to Consultant:
|
Joseph Chang
|
[Personal contact information redacted]
|
|
If to the Company:
|
Nu Skin Enterprises, Inc.
|
c/o General Counsel
|
|
75 W Center Street
|
|
Provo, Utah 84601
|
|
[Personal contact information redacted]
|
NU SKIN ENTERPRISES, INC.
|
|
/s/ Ryan S. Napierski
|
By:
|
Ryan S. Napierski | |
Its: President and CEO
|
||
2024-03-28
|
CONSULTANT
|
|
/s/ Joseph Y. Chang
|
|
Joseph Y. Chang
|
|
2024-03-28
|
1. |
I have reviewed this quarterly report on Form 10-Q of Nu Skin Enterprises, Inc.;
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and
for, the periods presented in this report;
|
4. |
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
this report based on such evaluation; and
|
(d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5. |
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of
directors (or persons performing the equivalent functions):
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and
report financial information; and
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: May 8, 2024
|
/s/ Ryan S. Napierski
|
|
Ryan S. Napierski
|
||
Chief Executive Officer
|
1. |
I have reviewed this quarterly report on Form 10-Q of Nu Skin Enterprises, Inc.;
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and
for, the periods presented in this report;
|
4. |
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
this report based on such evaluation; and
|
(d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5. |
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of
directors (or persons performing the equivalent functions):
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and
report financial information; and
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: May 8, 2024
|
/s/ James D. Thomas
|
|
James D. Thomas
|
||
Chief Financial Officer
|
1. |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
2. |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: May 8, 2024
|
/s/ Ryan S. Napierski
|
|
Ryan S. Napierski
|
||
Chief Executive Officer
|
1. |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
2. |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: May 8, 2024
|
/s/ James D. Thomas
|
|
James D. Thomas
|
||
Chief Financial Officer
|
Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares shares in Millions |
Mar. 31, 2024 |
Dec. 31, 2023 |
---|---|---|
Stockholders' equity: | ||
Common stock, shares authorized (in shares) | 500.0 | 500.0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares issued (in shares) | 90.6 | 90.6 |
Treasury stock (in shares) | 40.9 | 41.1 |
Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Consolidated Statements of Income [Abstract] | ||
Revenue | $ 417,306 | $ 481,462 |
Cost of sales | 123,242 | 133,588 |
Gross profit | 294,064 | 347,874 |
Operating expenses: | ||
Selling expenses | 153,542 | 188,124 |
General and administrative expenses | 124,566 | 133,899 |
Restructuring and impairment expenses | 7,134 | 9,787 |
Total operating expenses | 285,242 | 331,810 |
Operating income | 8,822 | 16,064 |
Interest expense | 7,325 | 4,888 |
Other income (expense), net | (396) | 3,412 |
Income before provision for income taxes | 1,101 | 14,588 |
Provision for income taxes | 1,634 | 3,212 |
Net (loss) income | $ (533) | $ 11,376 |
Net (loss) income per share (Note 6): | ||
Basic (in dollars per share) | $ (0.01) | $ 0.23 |
Diluted (in dollars per share) | $ (0.01) | $ 0.23 |
Weighted-average common shares outstanding: | ||
Basic (in shares) | 49,538 | 49,644 |
Diluted (in shares) | 49,538 | 50,058 |
Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Consolidated Statements of Comprehensive Income [Abstract] | ||
Net (loss) income | $ (533) | $ 11,376 |
Other comprehensive (loss) income, net of tax: | ||
Foreign currency translation adjustment, net of taxes of $- and $(68) for the three months ended March 31, 2024 and 2023, respectively | (10,104) | (2,139) |
Net unrealized gains/(losses) on cash flow hedges, net of taxes of $(435) and $175 for the three months ended March 31, 2024 and 2023, respectively | 1,574 | (635) |
Reclassification adjustment for realized losses/(gains) in current earnings, net of taxes of $572 and $475 for the three months ended March 31, 2024 and 2023, respectively | (2,071) | (1,722) |
Other comprehensive loss, net of tax | (10,601) | (4,496) |
Comprehensive (loss) income | $ (11,134) | $ 6,880 |
Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Other comprehensive (loss) income, net of tax: | ||
Foreign currency translation adjustment, tax | $ 0 | $ (68) |
Net unrealized gains/(losses) on foreign currency cash flow hedges, tax | (435) | 175 |
Reclassification adjustment for realized losses/(gains) in current earnings on cash flow hedges, tax | $ 572 | $ 475 |
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands |
Common Stock [Member]
Class A [Member]
|
Additional Paid-in Capital [Member] |
Treasury Stock [Member] |
Accumulated Other Comprehensive Loss [Member] |
Retained Earnings [Member] |
Total |
---|---|---|---|---|---|---|
Balance at beginning of period at Dec. 31, 2022 | $ 91 | $ 613,278 | $ (1,569,061) | $ (86,509) | $ 1,939,497 | $ 897,296 |
Stockholders' Equity [Roll Forward] | ||||||
Net (loss) income | 0 | 0 | 0 | 0 | 11,376 | 11,376 |
Other comprehensive loss, net of tax | 0 | 0 | 0 | (4,496) | 0 | (4,496) |
Exercise of employee stock options/vesting of stock awards | 0 | (5,797) | 9,981 | 0 | 0 | 4,184 |
Stock-based compensation | 0 | 4,002 | 0 | 0 | 0 | 4,002 |
Cash dividends | 0 | 0 | 0 | 0 | (19,392) | (19,392) |
Balance at end of period at Mar. 31, 2023 | 91 | 611,483 | (1,559,080) | (91,005) | 1,931,481 | 892,970 |
Balance at beginning of period at Dec. 31, 2023 | 91 | 621,853 | (1,570,440) | (100,006) | 1,870,470 | 821,968 |
Stockholders' Equity [Roll Forward] | ||||||
Net (loss) income | 0 | 0 | 0 | 0 | (533) | (533) |
Other comprehensive loss, net of tax | 0 | 0 | 0 | (10,601) | 0 | (10,601) |
Exercise of employee stock options/vesting of stock awards | 0 | (7,389) | 5,498 | 0 | 0 | (1,891) |
Stock-based compensation | 0 | 4,242 | 0 | 0 | 0 | 4,242 |
Cash dividends | 0 | 0 | 0 | 0 | (2,979) | (2,979) |
Balance at end of period at Mar. 31, 2024 | $ 91 | $ 618,706 | $ (1,564,942) | $ (110,607) | $ 1,866,958 | $ 810,206 |
Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - shares shares in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Stockholders' Equity [Roll Forward] | ||
Exercise of employee stock options (in shares) | 0.2 | 0.4 |
The Company |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2024 | |||
The Company [Abstract] | |||
The Company |
Nu Skin Enterprises, Inc. (the “Company”) is a holding company, with Nu Skin being the primary operating unit. Nu Skin develops and distributes
premium-quality, innovative beauty and wellness products that are sold worldwide under the Nu Skin, Pharmanex and ageLOC brands and a small number of other products and services. The Company reports revenue from nine segments, consisting of its seven
geographic Nu Skin segments—Americas,
which includes Canada, Latin America and the United States; Mainland China; Southeast Asia/Pacific, which includes Indonesia, Malaysia, the Philippines, Singapore, Thailand,
Vietnam, Australia, New Zealand, and other markets; Japan; Europe and Africa, which includes markets in Europe as well as South Africa; South Korea; and Hong Kong/Taiwan, which also includes Macau—and two Rhyz
segments—Manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz other, which includes other investments by its Rhyz business arm (the Company’s subsidiaries operating within each segment are collectively
referred to as the “Subsidiaries”).
|
Summary of Significant Accounting Policies |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies |
The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of
America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not
include all of the information and footnotes required by US GAAP for complete financial statements. The unaudited consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany accounts and transactions are eliminated in
consolidation. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered
necessary for a fair statement of the Company’s financial information as of March 31, 2024, and for the three-month periods ended March 31, 2024 and 2023. The results of operations of any interim period are not necessarily indicative of the results of operations to be
expected for the fiscal year. The consolidated balance sheet as of December 31, 2023 has been prepared using information from the audited financial statements at that date. For further information, refer to the consolidated financial statements and accompanying footnotes included in the Company’s Annual
Report on Form 10-K for the year ended December 31, 2023.
Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued
ASU 2023-07, Segment Reporting (Topic 280). The
amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (CODM), as well as the aggregate amount of other segment items
included in the reported measure of segment profit or loss. This ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss. Public
entities will be required to provide all annual disclosures currently required by Topic 280 in interim periods, and entities with a single reportable segment are required to provide all the disclosures required by the amendments in the update
and existing segment disclosures in Topic 280. This amendment is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal
years beginning after December 15, 2024, and requires retrospective adoption. Early adoption is permitted. The Company will adopt this standard with its fiscal 2024 annual filing. The Company is currently evaluating these new disclosure
requirements and the impact of adoption.
Reclassifications
Certain prior period amounts have been reclassified to conform with current presentation. The Company reclassified $4.9 million of interest expense from other income (expense), net to the
line on the consolidated statement of income for the first quarter of 2023. The reclassification had no impact on net income for the first quarter of 2023.Inventory
Inventories consist of the following (U.S. dollars in thousands):
Reserves of inventories consist of the following (U.S. dollars in thousands):
Revenue Recognition
Contract Liabilities – Customer Loyalty Programs
Contract liabilities, recorded as deferred revenue within the accrued expenses line in the consolidated balance sheets, include loyalty point
program deferrals with certain customers which are accounted for as a reduction in the transaction price and are generally recognized as points are redeemed for additional products.
The balance of deferred revenue related to contract liabilities as of March 31,
2024 and December 31, 2023 was $11.9 million and $12.6 million, respectively. The contract liabilities impact to revenue for the three-month periods ended March 31, 2024, and 2023 was an increase of $0.7 million and an increase of $1.3 million, respectively.
|
Goodwill |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill |
The Company’s reporting units for goodwill are its operating segments, which are also its reportable segments, with the exception of Rhyz other. The
Company’s Rhyz other segment consists of three
reporting units, which as of both March 31, 2024 and December 31, 2023 had goodwill of $12.6 million, $19.6 million and $4.7 million.
During the three months ended March 31, 2024, the Company determined that the recent decline in the Company’s stock price and corresponding market
capitalization was a triggering event that required the Company to perform a quantitative impairment analysis for all reporting units. Based on the analysis, the Company concluded the fair value of all reporting units were in excess of their carrying
amounts and no impairment charge was required. For goodwill, the estimated fair value of all reporting units exceeded the carrying value
by approximately 1% - 7%;
therefore the reporting units are considered to be at risk of future impairment. The reporting units’ fair values remain sensitive to unfavorable changes in assumptions utilized including revenue growth rates, profitability margins, estimated future
cash flows, and the discount rates that could result in impairment charges in a future period.
The following table presents goodwill allocated to the Company’s reportable segments
for the periods ended March 31, 2024 and December 31, 2023 (U.S. dollars in thousands):
|
Debt |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | ||||||||||||||||||||||||||||||||||||||||
Debt [Abstract] | ||||||||||||||||||||||||||||||||||||||||
Debt |
Credit Agreement
On June 14, 2022, the Company entered into an Amended and Restated Credit Agreement (the “Credit Agreement”) with several financial institutions as lenders and Bank
of America, N.A., as administrative agent, which amended and restated the 2018 Credit Agreement. The Credit Agreement provides for a $400
million term loan facility and a $500 million revolving credit facility, each with a term of five years. Both facilities bear interest at the SOFR, plus a margin based on the Company’s consolidated leverage ratio. Commitment fees payable under the Credit
Agreement are also based on the consolidated leverage ratio as defined in the Credit Agreement and range from 0.175% to 0.30% on the unused portion of the total lender commitments then in effect. The term loan facility amortizes in quarterly installments in amounts
resulting in an annual amortization of 2.5% during the first year and 5.0% during the second, third, fourth and fifth years after the closing date of the Credit Agreement, with the remainder payable at final maturity. The Credit Agreement is guaranteed by
certain of the Company’s domestic subsidiaries and collateralized by assets of such subsidiaries, including a pledge of 65% of the
capital stock of certain foreign subsidiaries. The Credit Agreement requires the Company to maintain a consolidated leverage ratio not exceeding 2.75
to 1.00 and a consolidated interest coverage ratio of no less than 3.00 to 1.00. As of March 31, 2024, the Company was in compliance
with all covenants under the Credit Agreement.
The following table summarizes the Company’s debt facilities as of March 31, 2024 and December 31, 2023:
|
Leases |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases |
As of March 31, 2024, the weighted average remaining
lease term was 8.2 and 3.5
years for operating and finance leases, respectively. As of March 31, 2024, the weighted average discount rate was 3.8% and 3.7% for operating and finance leases, respectively.
The components of lease expense were as follows (U.S. dollars in thousands):
Supplemental cash flow information related to leases was as follows (U.S. dollars in thousands):
Maturities of lease liabilities were as follows (U.S. dollars in thousands):
|
Capital Stock |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2024 | |||
Capital Stock [Abstract] | |||
Capital Stock |
Net income per share
Net income per share is computed based on the weighted-average number of common shares outstanding during the periods presented.
Additionally, diluted earnings per share data gives effect to all potentially dilutive common shares that were outstanding during the periods presented. For the three-month periods ended March 31, 2024 and 2023, the only dilutive common shares
outstanding relate to the Company’s outstanding stock awards and options. For the three-month periods ended March 31, 2024 and 2023, stock awards and options of 1.8 million and 0.1 million, respectively, were excluded from the
calculation of diluted earnings per share because they were anti-dilutive.
Dividends
In , the Company’s board of directors declared a quarterly cash dividend of $0.06
per share. This quarterly cash dividend of $3.0 million was paid on March 6, 2024 to stockholders of record on February 26, 2024. In , the board of directors declared a quarterly cash dividend of $0.06 per share to be paid on June 12, 2024 to stockholders of record on May 31, 2024.
Repurchase
of common stock
During the three-month periods ended March 31, 2024 and 2023, the Company
repurchased zero shares of its Class A common stock under its stock repurchase plans. As of March 31, 2024, $162.4 million was available for repurchases under the Company’s stock repurchase plan.
|
Fair Value and Equity Investments |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value and Equity Investments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value and Equity Investments |
Fair Value
The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximates fair values
due to the short-term nature of these instruments. The carrying value of debt approximates fair value due to the variable 30-day interest
rate. Fair value estimates are made at a specific point in time, based on relevant market information.
The FASB Codification defines fair value as the price that would be received to sell an asset or paid to transfer a liability in the principal or
most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. On a quarterly basis, the Company measures at fair value certain financial assets, including cash equivalents.
Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs
reflect the Company’s market assumptions. These two types of inputs have created the following fair-value hierarchy:
Accounting standards permit companies, at their option, to measure certain financial instruments and other eligible items at fair value. The Company
has elected not to apply the fair value option to existing eligible items beyond what is required by US GAAP.
The following tables present the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis (U.S. dollars in
thousands):
The following table provides a summary of changes in fair value of the Company’s Level 3 life insurance contracts (U.S. dollars in thousands):
Life insurance contracts: Accounting Standards
Codification (“ASC”) 820 preserves practicability exceptions to fair value measurements provided by other applicable provisions of U.S. GAAP. The guidance in ASC 715-30-35-60 allows a reporting entity, as a practical expedient, to use cash
surrender value or conversion value as an expedient for fair value when it is present. Accordingly, the Company determines the fair value of its life insurance contracts as the cash-surrender value of life insurance policies held in its Rabbi
Trust.
The following table provides a summary of changes in fair value of the Company’s Level 3 contingent consideration (U.S. dollars in thousands):
Contingent consideration: Contingent consideration represents the obligations
incurred in connection with acquisitions. The estimate of fair value of the contingent consideration obligations requires subjective assumptions to be made regarding the future business results, discount rates, discount periods and probabilities
assigned to various potential business result scenarios and was determined using probability assessments with respect to the likelihood of reaching various targets or of achieving certain milestones. The fair value measurement is based on significant
inputs unobservable in the market and thus represents a Level 3 measurement. Changes in current expectations of progress could change the probability of achieving the targets within the measurement periods and result in an increase or decrease in the
fair value of the contingent consideration obligation.
Equity Investments
The Company maintains equity investments in companies which are accounted for
under the measurement alternative described in ASC 321-10-35-2 for equity securities that lack readily determinable fair values. The
carrying amount of equity securities held by the Company without readily determinable fair values was $28.1 million at each of March 31, 2024 and December 31, 2023. During the three months ended September 30, 2021 the Company recognized $18.1 million upward fair value adjustments, based on the valuation
of additional equity issued by the investee which was deemed to be an observable transaction of a similar investment under ASC 321. The third quarter of 2021 gain was recorded within Other income (expense), net on the Consolidated Statement of Income. The upward fair value adjustment represents a nonrecurring fair value measurement based on observable price changes and is classified as a
Level 3 fair value measurement.
|
Income Taxes |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2024 | |||
Income Taxes [Abstract] | |||
Income Taxes |
Provision for income
taxes for the first quarter of 2024 was $1.6 million, compared to $3.2 million for the prior-year period. The effective tax rate for the first quarter 2024 was 148.4% of pre-tax income compared to 22.0% in the prior-year period.
The Company accounts for income taxes in accordance with ASC Topic 740 “Income Taxes.” These standards establish financial accounting and reporting
standards for the effects of income taxes that result from an enterprise’s activities during the current and preceding years. The Company takes an asset and liability approach for financial accounting and reporting of income taxes. The Company pays
income taxes in many foreign jurisdictions based on the profits realized in those jurisdictions, which can be significantly impacted by terms of intercompany transactions between the Company and its foreign affiliates. Deferred tax assets and
liabilities are created in this process. The Company has netted these deferred tax assets and deferred tax liabilities by jurisdiction. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be
ultimately realized. The Company had net deferred tax assets of $105.6 million and $105.0 million as of March 31, 2024 and December 31, 2023, respectively.
The Company evaluates its indefinite reinvestment assertions with respect to foreign earnings for each quarter. For all foreign earnings, the
Company accrues the applicable foreign income taxes. For the earnings that have been indefinitely reinvested, the Company does not accrue foreign withholding taxes. Undistributed earnings that the Company has indefinitely reinvested, for which no
foreign withholding taxes have been provided, aggregate to $60.0 million as of December 31, 2023. If the amount designated as indefinitely
reinvested as of December 31, 2023 was repatriated to the United States, the amount of incremental taxes would be approximately $6.0
million. The Company intends to utilize the indefinitely reinvested offshore earnings to fund foreign investments, specifically capital expenditures.
The Company files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. In 2009, the Company entered into a
voluntary program with the IRS called Compliance Assurance Process (“CAP”). The objective of CAP is to contemporaneously work with the IRS to achieve federal tax compliance and resolve all or most of the issues prior to filing of the tax return. As
of December 31, 2023, tax years through 2020 and 2022 have been audited and are effectively closed to further examination. For tax year 2021, the Company was in the Bridge phase of the CAP program, pursuant to which the IRS will not accept
disclosures, will not conduct reviews and will not provide letters of assurance for the Bridge years. There are limited circumstances that tax years in the Bridge phase will be opened for examination. For tax years 2023 and 2024, the Company has
been accepted in the IRS’s Bridge Plus program. The Company may elect to continue participating in CAP for future tax years; the Company may withdraw from the program at any time. With a few exceptions, the Company is no longer subject to state and
local income tax examination by tax authorities for the years before 2020. Foreign jurisdictions have varying lengths of statutes of limitations for income tax examinations. Some statutes are as short as three years and in certain markets may be as long as ten years.
The Company is currently under examination in certain foreign jurisdictions; however, the outcomes of those reviews are not yet determinable. The Company’s unrecognized tax benefits relate to multiple jurisdictions. Due to potential increases in
unrecognized tax benefits from the multiple jurisdictions in which the Company operates, as well as the expiration of various statutes of limitations, it is reasonably possible that the Company’s gross unrecognized tax benefits, net of foreign
currency adjustments, may increase in the next 12 months by approximately $2.0 to $3.0 million.
In 2021, as part of the Organization for Economic Co-operation and Development’s (“OECD”) Inclusive Framework, 140 member countries agreed to the
implementation of the Pillar Two Global Minimum Tax (“Pillar Two”) of 15%. The OECD continues to release additional guidance, including administrative guidance on how Pillar Two rules should be interpreted and applied by jurisdictions as they
adopt Pillar Two. A number of countries have utilized the administrative guidance as a starting point for legislation that went into effect January 1, 2024. Based on current enacted legislation, the Company anticipates the impact of Pillar Two to
be immaterial for 2024.
|
Derivatives and Hedging Activities |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivatives and Hedging Activities [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivatives and Hedging Activities |
Risk Management Objective of Using Derivatives
The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to
a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of
its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of
future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash
receipts and its known or expected cash payments principally related to the Company’s borrowings.
Cash Flow Hedges of Interest Rate Risk
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements.
To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in
exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. During 2024, such derivatives were used to hedge the variable cash flows associated with existing variable-rate
debt.
For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other
Comprehensive Income and subsequently reclassified into interest expense/income in the same period(s) during which the hedged transaction affects earnings. Amounts reported in accumulated other comprehensive income related to derivatives will be
reclassified to interest expense/income as interest payments are made/received on the Company’s variable-rate debt. During the next twelve months, the Company estimates that an additional $9.5 million will be reclassified as a reduction to interest expense.
As of March 31, 2024 and December 31, 2023, the Company had four outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk with a total notional amount of $200 million.
Fair Values of Derivative Instruments on the Balance Sheet
The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the Balance Sheet:
Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Loss
The tables below present the effect of cash flow hedge accounting on Accumulated Other Comprehensive Loss.
|
Segment Information |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Information [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Information |
The Company reports revenue from nine
segments, consisting of its seven geographic Nu Skin segments—Americas,
Mainland China, Southeast Asia/Pacific, South Korea, Japan, Europe & Africa, and Hong Kong/Taiwan—and two Rhyz Investments
segments—Manufacturing and Rhyz other. The Nu Skin other category includes miscellaneous corporate revenue and related adjustments. The Rhyz other segment includes other investments by our Rhyz business arm. These segments reflect the way the chief
operating decision maker evaluates the Company’s business performance and allocates resources. Reported revenue includes only the revenue generated by sales to
external customers.
Profitability by segment as determined under US GAAP is driven primarily by the Company’s transfer pricing policies. Segment contribution,
which is the Company’s segment profitability metric presented in the table below, excludes certain intercompany charges, specifically royalties, license fees, transfer pricing, discrete charges and other miscellaneous items. These charges have been
included in Corporate and other expenses. Corporate and other expenses also include costs related to the Company’s executive and administrative offices, information technology, research and development, and marketing and supply chain functions not
recorded at the segment level.
Effective June 2023, the Company closed its Israel market. As a result the EMEA
segment has been renamed Europe & Africa.
The accounting policies of the segments are the same as those described in Note 2 – Summary of Significant Accounting Policies. The Company
evaluates the performance of its segments based on revenue and segment contribution. Each segment records direct expenses related to its employees and its operations.
Summarized financial information for the Company’s reportable segments is shown in the following tables. Asset information is not reviewed
or included with the Company’s internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment.
Revenue by Segment
Segment Contribution
Depreciation and Amortization
Capital Expenditures
|
Commitments and Contingencies |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2024 | |||
Commitments and Contingencies [Abstract] | |||
Commitments and Contingencies |
The Company is subject to government regulations pertaining to product formulation, labeling and packaging, product claims and advertising, and the
Company’s direct selling system. The Company is also subject to the jurisdiction of numerous foreign tax and customs authorities. Any assertions or determination that either the Company or the Company’s sales force is not in compliance with existing
statutes, laws, rules or regulations could have a material adverse effect on the Company’s operations. In addition, in any country or jurisdiction, the adoption of new statutes, laws, rules or regulations or changes in the interpretation of existing
statutes, laws, rules or regulations could have a material adverse effect on the Company and its operations. No assurance can be given that the Company’s compliance with applicable statutes, laws, rules and regulations will not be challenged by
foreign authorities or that such challenges will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. The Company and its Subsidiaries are defendants in litigation, investigations and other
proceedings involving various matters. Management believes that the ultimate liability arising from such claims and contingencies, if any, is not likely to have a material adverse effect on the Company’s consolidated financial condition, results of
operations or cash flows.
The Company is subject to regular audits by federal, state and foreign tax authorities. These audits may result in additional tax liabilities. The
Company believes it has appropriately provided for income taxes for all years. Several factors drive the calculation of its tax reserves. Some of these factors include: (i) the expiration of various statutes of limitations; (ii) changes in tax law
and regulations; (iii) issuance of tax rulings; and (iv) settlements with tax authorities. Changes in any of these factors may result in adjustments to the Company’s reserves, which would impact its reported financial results.
|
Acquisitions |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2024 | |||
Acquisitions [Abstract] | |||
Acquisitions |
In April 2023, the
Company acquired 60 percent of LifeDNA, Inc. (“LifeDNA”), a DNA assessment company. Consideration paid included $4.0 million of cash, along with the conversion of a previous $3.0 million Simple Agreement for Future Equity (“SAFE”), and a $0.2 million convertible note. The
acquisition enables the Company to continue to expand its digital tools. The Company allocated the fair value of $12.0 million to the
assets acquired and liabilities assumed at estimated fair values. The estimated fair value of assets acquired included $7.3 million of
intangible assets, $1.7 million of cash, $0.1
million of current assets, $0.9 million of accrued liabilities and also resulted in a deferred tax liability of $0.9 million. The excess purchase price over the aggregate fair value of assets acquired less liabilities assumed of $4.7 million was recorded as goodwill. The goodwill recognized is attributable primarily to expected synergies. None of the goodwill is expected to be
deductible for income tax purposes. The intangible assets acquired comprised $0.6 million of customer relationships, $1.7 million of technology, $1.0 million
of tradenames and $4.1 million of other intangibles. The intangibles were assigned useful lives of 7 years for the technology, tradenames and other intangibles, and 2 years for the customer relationships. All the goodwill was assigned to our Rhyz other segment. The numbers above are stated net of measurement period adjustments recorded during the fourth quarter of 2023 of $1.1
million to deferred tax liability and goodwill. The allocation of the fair value of assets acquired and liabilities assumed for the acquisition was finalized during the three months ended December 31, 2023.
In June 2023, the
Company acquired 100 percent ownership in Beauty Biosciences, LLC (“BeautyBio”), making BeautyBio a wholly owned subsidiary of the
Company. The acquisition expands the Company’s product and device offerings within its Rhyz segment. The purchase price for BeautyBio was $75.0
million, net of cash acquired of $1.5 million, all payable in cash. The Company allocated the gross purchase price of $76.5 million to the assets acquired and liabilities assumed at estimated fair values. The estimated fair value of assets acquired included $43.0 million of intangible assets, $1.5
million of cash, $3.5 million of accounts receivable, $10.3 million of inventory, $0.8 million of prepaid and other assets, $1.0 million of fixed assets, $1.2
million of an ROU operating lease asset and corresponding lease liability, $2.5 million of accounts payable and accrued liabilities and
also resulted in a deferred tax liability of $0.7 million. The excess purchase price over the aggregate fair value of assets acquired
less liabilities assumed of $19.6 million was recorded as goodwill. The goodwill recognized is attributable primarily to expected
synergies. None of the goodwill is expected to be deductible for income tax purposes. The intangible assets acquired comprised $18.4
million of customer relationships, $2.3 million of technology, $20.9 million of tradenames and $1.4 million of other intangibles.
The intangibles were assigned useful lives of approximately 19 years for the technology and tradenames, approximately 9 years for the customer relationships and 3 years
for the other intangibles. All the goodwill was assigned to our Rhyz other segment. The numbers above are stated net of measurement period adjustments recorded during the fourth quarter of 2023 of $(1.2) million to accounts receivable, $(0.7) million of
inventory, $(0.5) million of accrued liabilities, $0.7 million of deferred tax liability, $(0.3) of intangible assets and $2.4 million of goodwill. The allocation of the fair value of assets acquired and liabilities assumed for the acquisition was finalized during the three
months ended March 31, 2024.
The financial results of LifeDNA and BeautyBio are included in the Rhyz other segment from the date of acquisition. For the three months ended March 31, 2024, the Company included $5.3 million of revenue from these acquisitions. The unaudited pro forma revenue for the Company, including LifeDNA and BeautyBio, as if the acquisitions occurred on
January 1, 2023, would have been $486.3 million for the three months ended March 31, 2023.
|
Restructuring |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring |
In the third quarter of 2022, the Company adopted a
strategic plan (“2022 Plan”) to focus resources on the Company’s strategic priorities and optimize future growth and profitability. The global program includes workforce reductions and footprint optimization. The Company incurred total
charges under the program of approximately $53.3 million, with $40.8 million in cash charges of severance and lease termination cost and approximately $12.5 million of non-cash charges of impairment of fixed assets, acceleration of depreciation and impairment of other intangibles related to the footprint optimization. During 2022, the Company incurred
charges to be settled in cash of $20.1 million in severance charges, $7.4 million in lease termination cost, and $5.2 million in
other associated cost, and non-cash charges of $8.2 million in fixed asset impairments, $0.9 million in accelerated depreciation and $1.7 million in
impairment of other intangibles. During 2022, the Company made cash payments of $21.0 million related to this global program,
leaving an ending restructuring accrual of $11.7 million. During the first quarter and full year of 2023, the Company incurred
charges to be settled in cash of $4.0 million in severance charges, $1.9 million in lease termination cost, and $2.2
million in other associated cost, and non-cash charges of $1.7 million in accelerated depreciation. In 2023, the Company made cash payments of $19.8 million, leaving no restructuring accrual related to this plan as
of December 31, 2023.
Restructuring
expense by segment - 2022 Plan
In the fourth quarter of 2023, the Company adopted another strategic plan (“2023 Plan”) to focus resources on the Company’s global priorities and
optimize future growth and profitability. The global program includes workforce reductions. The Company estimates total charges under the program will approximate $20–$25 million in cash charges of severance. The Company expects to substantially complete the
program during the first half of 2024. During the fourth quarter of 2023, the Company incurred charges to be settled in cash of $10.0
million in severance charges. During the fourth quarter of 2023, the Company made cash payments of $0.3 million, leaving an ending
restructuring accrual of $9.7 million. During the first quarter of 2024, the Company incurred charges to be settled in cash of $4.1 million in severance charges and $2.0
million in other associated cost, and non-cash charges of $1.0 million in write-down of assets. During the first quarter of 2024, the
Company made cash payments of $7.0 million, leaving an ending restructuring accrual of $8.8 million.
Restructuring expense by
segment – 2023 Plan
|
Insider Trading Arrangements |
3 Months Ended |
---|---|
Mar. 31, 2024 | |
Insider Trading Arrangements [Line Items] | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Summary of Significant Accounting Policies (Policies) |
3 Months Ended |
---|---|
Mar. 31, 2024 | |
Summary of Significant Accounting Policies [Abstract] | |
Basis of Accounting | The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. |
Consolidation | The unaudited consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. |
Accounting Pronouncements |
Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued
ASU 2023-07, Segment Reporting (Topic 280). The
amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (CODM), as well as the aggregate amount of other segment items
included in the reported measure of segment profit or loss. This ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss. Public
entities will be required to provide all annual disclosures currently required by Topic 280 in interim periods, and entities with a single reportable segment are required to provide all the disclosures required by the amendments in the update
and existing segment disclosures in Topic 280. This amendment is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal
years beginning after December 15, 2024, and requires retrospective adoption. Early adoption is permitted. The Company will adopt this standard with its fiscal 2024 annual filing. The Company is currently evaluating these new disclosure
requirements and the impact of adoption.
|
Reclassifications |
Reclassifications
Certain prior period amounts have been reclassified to conform with current presentation. The Company reclassified $4.9 million of interest expense from other income (expense), net to the
line on the consolidated statement of income for the first quarter of 2023. The reclassification had no impact on net income for the first quarter of 2023. |
Revenue Recognition |
Revenue Recognition
Contract Liabilities – Customer Loyalty Programs
Contract liabilities, recorded as deferred revenue within the accrued expenses line in the consolidated balance sheets, include loyalty point
program deferrals with certain customers which are accounted for as a reduction in the transaction price and are generally recognized as points are redeemed for additional products.
The balance of deferred revenue related to contract liabilities as of March 31,
2024 and December 31, 2023 was $11.9 million and $12.6 million, respectively. The contract liabilities impact to revenue for the three-month periods ended March 31, 2024, and 2023 was an increase of $0.7 million and an increase of $1.3 million, respectively.
|
Summary of Significant Accounting Policies (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories |
Inventories consist of the following (U.S. dollars in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Reserves |
Reserves of inventories consist of the following (U.S. dollars in thousands):
|
Goodwill (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill |
The following table presents goodwill allocated to the Company’s reportable segments
for the periods ended March 31, 2024 and December 31, 2023 (U.S. dollars in thousands):
|
Debt (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | ||||||||||||||||||||||||||||||||||||||
Debt [Abstract] | ||||||||||||||||||||||||||||||||||||||
Debt Facilities |
The following table summarizes the Company’s debt facilities as of March 31, 2024 and December 31, 2023:
|
Leases (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Components of Lease Expense |
The components of lease expense were as follows (U.S. dollars in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplemental Cash Flow Information Related to Leases |
Supplemental cash flow information related to leases was as follows (U.S. dollars in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maturities of Lease Liabilities |
Maturities of lease liabilities were as follows (U.S. dollars in thousands):
|
Fair Value and Equity Investments (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value and Equity Investments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assets and Liabilities Measured at Fair Value on a Recurring Basis |
The following tables present the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis (U.S. dollars in
thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Changes in Fair Value of Level 3 Life Insurance Contracts |
The following table provides a summary of changes in fair value of the Company’s Level 3 life insurance contracts (U.S. dollars in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Changes in Fair Value of Level 3 Contingent Consideration |
The following table provides a summary of changes in fair value of the Company’s Level 3 contingent consideration (U.S. dollars in thousands):
|
Derivatives and Hedging Activities (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivatives and Hedging Activities [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Derivative Instruments on the Balance Sheet |
The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the Balance Sheet:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Loss |
The tables below present the effect of cash flow hedge accounting on Accumulated Other Comprehensive Loss.
|
Segment Information (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Information [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue by Segment |
Revenue by Segment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Contribution |
Segment Contribution
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Depreciation and Amortization and Capital Expenditures |
Depreciation and Amortization
Capital Expenditures
|
Restructuring (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2022 Plan [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring Expense by Segment |
Restructuring
expense by segment - 2022 Plan
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2023 Plan [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring Expense by Segment |
Restructuring expense by
segment – 2023 Plan
|
The Company (Details) |
3 Months Ended |
---|---|
Mar. 31, 2024
Segment
| |
The Company [Abstract] | |
Number of reportable segments | 9 |
Number of geographic segments | 7 |
Number of Rhyz segments | 2 |
Summary of Significant Accounting Policies, Reclassifications (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Interest Expense [Abstract] | ||
Interest expense | $ 7,325 | $ 4,888 |
Reclassification [Member] | Other Income (Expense), Net [Member] | ||
Interest Expense [Abstract] | ||
Interest expense | (4,900) | |
Reclassification [Member] | Interest Expense [Member] | ||
Interest Expense [Abstract] | ||
Interest expense | $ 4,900 |
Summary of Significant Accounting Policies, Inventory (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Dec. 31, 2023 |
|
Inventories [Abstract] | |||
Raw materials | $ 133,600 | $ 140,133 | |
Finished goods | 131,500 | 139,845 | |
Total Inventory, net | 265,100 | $ 279,978 | |
Valuation Allowance [Roll Forward] | |||
Beginning balance | 83,378 | $ 37,267 | |
Additions | 2,003 | 3,267 | |
Write-offs | (4,862) | (4,518) | |
Ending balance | $ 80,519 | $ 36,016 |
Summary of Significant Accounting Policies, Revenue Recognition (Details) - USD ($) $ in Millions |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Dec. 31, 2023 |
|
Contract Liabilities - Customer Loyalty Programs [Abstract] | |||
Contract liabilities for customer loyalty programs | $ 11.9 | $ 12.6 | |
Contract liabilities, increase to revenue | $ 0.7 | $ 1.3 |
Debt, Debt Facilities (Details) - USD ($) $ in Thousands |
3 Months Ended | ||||||
---|---|---|---|---|---|---|---|
Mar. 31, 2024 |
Dec. 31, 2023 |
Jun. 14, 2022 |
|||||
Debt [Abstract] | |||||||
Term of variable rate | 30 days | ||||||
Current portion of long-term debt | $ 30,000 | $ 25,000 | |||||
Credit Agreement [Member] | |||||||
Debt [Abstract] | |||||||
Unamortized debt issuance costs | 1,800 | 2,000 | |||||
Credit Agreement Term Loan Facility [Member] | |||||||
Debt [Abstract] | |||||||
Original principal amount | 400,000 | $ 400,000 | |||||
Balance | [1],[2] | $ 375,000 | 385,000 | ||||
Interest rate | Variable 30 day: 7.43% | ||||||
Interest rate | 7.43% | ||||||
Term of variable rate | 30 days | ||||||
Repayment terms | 21% of the principal amount is payable in increasing quarterly installments over a five-year period that began on September 30, 2022, with the remainder payable at the end of the five-year term. | ||||||
Percentage of principal payable in installments | 21.00% | ||||||
Term of loan | 5 years | ||||||
Current portion of long-term debt | $ 20,000 | 25,000 | |||||
Credit Agreement Revolving Credit Facility [Member] | |||||||
Debt [Abstract] | |||||||
Balance | [1],[2] | $ 110,000 | 120,000 | ||||
Interest rate | Variable 30 day: 7.43% | ||||||
Interest rate | 7.43% | ||||||
Term of variable rate | 30 days | ||||||
Repayment terms | Revolving line of credit expires June 14, 2027. | ||||||
Term of loan | 5 years | ||||||
Current portion of long-term debt | $ 10,000 | $ 0 | |||||
|
Capital Stock, Net Income per Share (Details) - shares shares in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Stock Awards and Options [Member] | ||
Net Income per Share [Abstract] | ||
Anti-dilutive shares excluded from calculation of diluted earnings per share (in shares) | 1.8 | 0.1 |
Capital Stock, Dividends (Details) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | 3 Months Ended | ||
---|---|---|---|---|
May 31, 2024 |
Feb. 28, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Dividends per Share [Abstract] | ||||
Payment of cash dividends | $ 2,979 | $ 19,392 | ||
Dividend Declared 2024-Q1 [Member] | ||||
Dividends per Share [Abstract] | ||||
Dividend payable, date declared | 2024-02 | |||
Dividend payable per share (in dollars per share) | $ 0.06 | |||
Payment of cash dividends | $ 3,000 | |||
Dividend payable, date paid | Mar. 06, 2024 | |||
Dividend payable, date of record | Feb. 26, 2024 | |||
Dividend Declared 2024-Q2 [Member] | Subsequent Event [Member] | ||||
Dividends per Share [Abstract] | ||||
Dividend payable, date declared | 2024-05 | |||
Dividend payable per share (in dollars per share) | $ 0.06 | |||
Dividend payable, date paid | Jun. 12, 2024 | |||
Dividend payable, date of record | May 31, 2024 |
Capital Stock, Repurchase of Common Stock (Details) - USD ($) shares in Millions, $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Repurchases of Common Stock [Abstract] | ||
Amount available for repurchases | $ 162.4 | |
Treasury Stock [Member] | ||
Repurchases of Common Stock [Abstract] | ||
Class A common stock repurchased (in shares) | 0 | 0 |
Fair Value and Equity Investments, Equity Investments (Details) - Equity Securities [Member] - USD ($) $ in Millions |
3 Months Ended | ||
---|---|---|---|
Sep. 30, 2021 |
Mar. 31, 2024 |
Dec. 31, 2023 |
|
Equity Investments [Abstract] | |||
Carrying amount of equity securities without readily determinable fair values | $ 28.1 | $ 28.1 | |
Other Income (Expense), Net [Member] | |||
Equity Investments [Abstract] | |||
Upward fair value adjustments on equity securities | $ 18.1 |
Income Taxes (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Dec. 31, 2023 |
|
Income Taxes [Abstract] | |||
Provision for income taxes | $ 1,634 | $ 3,212 | |
Effective tax rate | 148.40% | 22.00% | |
Net deferred tax assets | $ 105,600 | $ 105,000 | |
Undistributed earnings of non-U.S. subsidiaries | 60,000 | ||
Incremental taxes if undistributed earnings on non-U.S. subsidiaries were repatriated | $ 6,000 | ||
Minimum [Member] | |||
Income Taxes [Abstract] | |||
Increase in unrecognized tax benefits within the next 12 months that is reasonably possible | 2,000 | ||
Maximum [Member] | |||
Income Taxes [Abstract] | |||
Increase in unrecognized tax benefits within the next 12 months that is reasonably possible | $ 3,000 | ||
Foreign Jurisdictions [Member] | Minimum [Member] | |||
Income Taxes [Abstract] | |||
Statute of limitations related to income tax examinations | 3 years | ||
Foreign Jurisdictions [Member] | Maximum [Member] | |||
Income Taxes [Abstract] | |||
Statute of limitations related to income tax examinations | 10 years |
Derivatives and Hedging Activities, Fair Value of Derivative Instruments on the Balance Sheet (Details) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024
USD ($)
Derivatives
|
Dec. 31, 2023
USD ($)
Derivatives
|
|
Derivatives and Hedging Activities [Abstract] | ||
Loss to be reclassified to interest expense during next twelve months | $ (9,500) | |
Number of outstanding derivatives held | Derivatives | 4 | 4 |
Notional amount | $ 200,000 | $ 200,000 |
Interest Rate Swaps [Member] | Designated as Hedging Instrument [Member] | Prepaid Expenses and Other [Member] | ||
Derivatives and Hedging Activities [Abstract] | ||
Fair value, asset | 9,451 | 8,955 |
Interest Rate Swaps [Member] | Designated as Hedging Instrument [Member] | Other Assets [Member] | ||
Derivatives and Hedging Activities [Abstract] | ||
Fair value, asset | $ 2,603 | $ 3,734 |
Derivatives and Hedging Activities, Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Loss (Details) - Interest Rate Swaps [Member] - Designated as Hedging Instrument [Member] - Cash Flow Hedges [Member] - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Other Income (Expense), Net [Member] | ||
Derivatives and Hedging Activities [Abstract] | ||
Gain reclassified from accumulated other comprehensive loss into income | $ 2,643 | $ 2,197 |
Other Comprehensive Loss [Member] | ||
Derivatives and Hedging Activities [Abstract] | ||
Gain (loss) recognized in OCI | $ 2,009 | $ (810) |
Segment Information, Segment Contribution (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Segment Contribution [Abstract] | ||
Operating income | $ 8,822 | $ 16,064 |
Interest expense | 7,325 | 4,888 |
Other income (expense), net | (396) | 3,412 |
Income before provision for income taxes | 1,101 | 14,588 |
Operating Segment [Member] | ||
Segment Contribution [Abstract] | ||
Operating income | 69,170 | 86,955 |
Operating Segment [Member] | Nu Skin [Member] | ||
Segment Contribution [Abstract] | ||
Operating income | 73,145 | 90,288 |
Operating Segment [Member] | Americas [Member] | ||
Segment Contribution [Abstract] | ||
Operating income | 14,976 | 16,250 |
Operating Segment [Member] | Mainland China [Member] | ||
Segment Contribution [Abstract] | ||
Operating income | 12,253 | 13,612 |
Operating Segment [Member] | Southeast Asia/Pacific [Member] | ||
Segment Contribution [Abstract] | ||
Operating income | 11,084 | 12,471 |
Operating Segment [Member] | Japan [Member] | ||
Segment Contribution [Abstract] | ||
Operating income | 12,006 | 12,908 |
Operating Segment [Member] | Europe & Africa [Member] | ||
Segment Contribution [Abstract] | ||
Operating income | 3,276 | 3,638 |
Operating Segment [Member] | South Korea [Member] | ||
Segment Contribution [Abstract] | ||
Operating income | 12,183 | 23,575 |
Operating Segment [Member] | Hong Kong/Taiwan [Member] | ||
Segment Contribution [Abstract] | ||
Operating income | 7,367 | 7,834 |
Operating Segment [Member] | Rhyz Investments [Member] | ||
Segment Contribution [Abstract] | ||
Operating income | (3,975) | (3,333) |
Operating Segment [Member] | Manufacturing [Member] | ||
Segment Contribution [Abstract] | ||
Operating income | 1,967 | (1,373) |
Operating Segment [Member] | Rhyz Other [Member] | ||
Segment Contribution [Abstract] | ||
Operating income | (5,942) | (1,960) |
Corporate and Other [Member] | ||
Segment Contribution [Abstract] | ||
Operating income | $ (60,348) | $ (70,891) |
Segment Information, Depreciation and Amortization and Capital Expenditures (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Summarized Financial Information [Abstract] | ||
Depreciation and amortization | $ 18,437 | $ 16,983 |
Capital expenditures | 12,281 | 11,487 |
Operating Segments [Member] | Nu Skin [Member] | ||
Summarized Financial Information [Abstract] | ||
Depreciation and amortization | 4,306 | 5,363 |
Capital expenditures | 3,104 | 4,737 |
Operating Segments [Member] | Americas [Member] | ||
Summarized Financial Information [Abstract] | ||
Depreciation and amortization | 105 | 66 |
Capital expenditures | 21 | 100 |
Operating Segments [Member] | Mainland China [Member] | ||
Summarized Financial Information [Abstract] | ||
Depreciation and amortization | 2,774 | 2,775 |
Capital expenditures | 2,689 | 4,035 |
Operating Segments [Member] | Southeast Asia/Pacific [Member] | ||
Summarized Financial Information [Abstract] | ||
Depreciation and amortization | 249 | 280 |
Capital expenditures | 9 | 64 |
Operating Segments [Member] | Japan [Member] | ||
Summarized Financial Information [Abstract] | ||
Depreciation and amortization | 81 | 1,054 |
Capital expenditures | 0 | 5 |
Operating Segments [Member] | Europe & Africa [Member] | ||
Summarized Financial Information [Abstract] | ||
Depreciation and amortization | 273 | 282 |
Capital expenditures | 165 | 119 |
Operating Segments [Member] | South Korea [Member] | ||
Summarized Financial Information [Abstract] | ||
Depreciation and amortization | 245 | 453 |
Capital expenditures | 22 | 154 |
Operating Segments [Member] | Hong Kong/Taiwan [Member] | ||
Summarized Financial Information [Abstract] | ||
Depreciation and amortization | 579 | 453 |
Capital expenditures | 198 | 260 |
Operating Segments [Member] | Rhyz Investments [Member] | ||
Summarized Financial Information [Abstract] | ||
Depreciation and amortization | 5,221 | 4,016 |
Capital expenditures | 1,984 | 1,481 |
Operating Segments [Member] | Manufacturing [Member] | ||
Summarized Financial Information [Abstract] | ||
Depreciation and amortization | 3,335 | 3,424 |
Capital expenditures | 1,349 | 1,481 |
Operating Segments [Member] | Rhyz Other [Member] | ||
Summarized Financial Information [Abstract] | ||
Depreciation and amortization | 1,886 | 592 |
Capital expenditures | 635 | 0 |
Corporate and Other [Member] | ||
Summarized Financial Information [Abstract] | ||
Depreciation and amortization | 8,910 | 7,604 |
Capital expenditures | $ 7,193 | $ 5,269 |
Acquisitions, LifeDNA (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | |
---|---|---|---|
Apr. 30, 2023 |
Mar. 31, 2024 |
Dec. 31, 2023 |
|
Fair Value of Assets Acquired [Abstract] | |||
Goodwill | $ 230,768 | $ 230,768 | |
LifeDNA [Member] | |||
Acquisitions [Abstract] | |||
Percentage interest acquired | 60.00% | ||
Consideration paid, cash | $ 4,000 | ||
Consideration paid, conversion of previous SAFE | 3,000 | ||
Consideration paid, convertible note | 200 | ||
Gross purchase price | 12,000 | ||
Fair Value of Assets Acquired [Abstract] | |||
Intangible assets | 7,300 | ||
Cash | 1,700 | ||
Current assets | 100 | ||
Accrued liabilities | 900 | ||
Deferred tax liability | 900 | ||
Goodwill | 4,700 | ||
Measurement period adjustments to deferred tax liability and goodwill | $ 1,100 | ||
LifeDNA [Member] | Customer Relationships [Member] | |||
Fair Value of Assets Acquired [Abstract] | |||
Intangible assets | 600 | ||
Useful life | 2 years | ||
LifeDNA [Member] | Technology [Member] | |||
Fair Value of Assets Acquired [Abstract] | |||
Intangible assets | 1,700 | ||
Useful life | 7 years | ||
LifeDNA [Member] | Tradenames [Member] | |||
Fair Value of Assets Acquired [Abstract] | |||
Intangible assets | 1,000 | ||
Useful life | 7 years | ||
LifeDNA [Member] | Other Intangibles [Member] | |||
Fair Value of Assets Acquired [Abstract] | |||
Intangible assets | $ 4,100 | ||
Useful life | 7 years |
Acquisitions, BeautyBio (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | |
---|---|---|---|
Jun. 30, 2023 |
Mar. 31, 2024 |
Dec. 31, 2023 |
|
Fair Value of Assets Acquired [Abstract] | |||
Goodwill | $ 230,768 | $ 230,768 | |
BeautyBio [Member] | |||
Acquisitions [Abstract] | |||
Percentage interest acquired | 100.00% | ||
Purchase price, net of cash acquired | $ 75,000 | ||
Cash acquired | 1,500 | ||
Gross purchase price | 76,500 | ||
Fair Value of Assets Acquired [Abstract] | |||
Intangible assets | 43,000 | ||
Cash | 1,500 | ||
Accounts receivable | 3,500 | ||
Inventory | 10,300 | ||
Prepaid and other assets | 800 | ||
Fixed assets | 1,000 | ||
ROU operating lease asset | 1,200 | ||
Lease liability | 1,200 | ||
Accounts payable and accrued liabilities | 2,500 | ||
Deferred tax liability | 700 | ||
Goodwill | 19,600 | ||
Measurement period adjustment to accounts receivable | (1,200) | ||
Measurement period adjustment to inventory | (700) | ||
Measurement period adjustment to accrued liabilities | (500) | ||
Measurement period adjustment to deferred tax liability | 700 | ||
Measurement period adjustment to intangible assets | (300) | ||
Measurement period adjustment to goodwill | $ 2,400 | ||
BeautyBio [Member] | Customer Relationships [Member] | |||
Fair Value of Assets Acquired [Abstract] | |||
Intangible assets | 18,400 | ||
Useful life | 9 years | ||
BeautyBio [Member] | Technology [Member] | |||
Fair Value of Assets Acquired [Abstract] | |||
Intangible assets | 2,300 | ||
Useful life | 19 years | ||
BeautyBio [Member] | Tradenames [Member] | |||
Fair Value of Assets Acquired [Abstract] | |||
Intangible assets | 20,900 | ||
Useful life | 19 years | ||
BeautyBio [Member] | Other Intangibles [Member] | |||
Fair Value of Assets Acquired [Abstract] | |||
Intangible assets | $ 1,400 | ||
Useful life | 3 years |
Acquisitions, Revenue and Pro Forma Revenue (Details) - LifeDNA and BeautyBio [Member] - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Acquisitions [Abstract] | ||
Unaudited pro forma revenue as if acquisitions occurred on January 1, 2023 | $ 486.3 | |
Rhyz Other [Member] | ||
Acquisitions [Abstract] | ||
Revenue since acquisitions | $ 5.3 |
Restructuring, 2022 Plan (Details) - USD ($) $ in Thousands |
3 Months Ended | 12 Months Ended | 15 Months Ended | ||
---|---|---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Mar. 31, 2023 |
|
Restructuring [Abstract] | |||||
Restructuring expense | $ 7,134 | $ 9,787 | |||
2022 Plan [Member] | |||||
Restructuring [Abstract] | |||||
Cash restructuring charges | $ 40,800 | ||||
Non-cash restructuring charges | 12,500 | ||||
Severance charges | 4,000 | $ 4,000 | $ 20,100 | ||
Lease termination cost | 1,900 | 1,900 | 7,400 | ||
Other associated restructuring costs | 2,200 | 2,200 | 5,200 | ||
Impairment of fixed assets | 8,200 | ||||
Accelerated depreciation | 1,700 | 1,700 | 900 | ||
Impairment of other intangible assets | 1,700 | ||||
Cash payments | 19,800 | 21,000 | |||
Ending restructuring accrual | $ 0 | 11,700 | |||
Restructuring expense | 9,787 | 43,494 | 53,281 | ||
2022 Plan [Member] | Operating Segment [Member] | Nu Skin [Member] | |||||
Restructuring [Abstract] | |||||
Restructuring expense | 4,024 | 23,516 | 27,540 | ||
2022 Plan [Member] | Operating Segment [Member] | Americas [Member] | |||||
Restructuring [Abstract] | |||||
Restructuring expense | 918 | 1,687 | 2,605 | ||
2022 Plan [Member] | Operating Segment [Member] | Mainland China [Member] | |||||
Restructuring [Abstract] | |||||
Restructuring expense | 1,352 | 13,181 | 14,533 | ||
2022 Plan [Member] | Operating Segment [Member] | Southeast Asia/Pacific [Member] | |||||
Restructuring [Abstract] | |||||
Restructuring expense | 131 | 1,809 | 1,940 | ||
2022 Plan [Member] | Operating Segment [Member] | Japan [Member] | |||||
Restructuring [Abstract] | |||||
Restructuring expense | 1,515 | 699 | 2,214 | ||
2022 Plan [Member] | Operating Segment [Member] | Europe & Africa [Member] | |||||
Restructuring [Abstract] | |||||
Restructuring expense | (113) | 2,143 | 2,030 | ||
2022 Plan [Member] | Operating Segment [Member] | South Korea [Member] | |||||
Restructuring [Abstract] | |||||
Restructuring expense | 422 | 1,533 | 1,955 | ||
2022 Plan [Member] | Operating Segment [Member] | Hong Kong/Taiwan [Member] | |||||
Restructuring [Abstract] | |||||
Restructuring expense | (201) | 2,464 | 2,263 | ||
2022 Plan [Member] | Operating Segment [Member] | Rhyz Investments [Member] | |||||
Restructuring [Abstract] | |||||
Restructuring expense | 13 | 401 | 414 | ||
2022 Plan [Member] | Operating Segment [Member] | Manufacturing [Member] | |||||
Restructuring [Abstract] | |||||
Restructuring expense | 13 | 401 | 414 | ||
2022 Plan [Member] | Operating Segment [Member] | Rhyz Other [Member] | |||||
Restructuring [Abstract] | |||||
Restructuring expense | 0 | 0 | 0 | ||
2022 Plan [Member] | Corporate and Other [Member] | |||||
Restructuring [Abstract] | |||||
Restructuring expense | $ 5,750 | $ 19,577 | $ 25,327 |
Restructuring, 2023 Plan (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2024 |
Dec. 31, 2023 |
Mar. 31, 2023 |
Mar. 31, 2024 |
|
Restructuring [Abstract] | ||||
Restructuring expense | $ 7,134 | $ 9,787 | ||
2023 Plan [Member] | ||||
Restructuring [Abstract] | ||||
Severance charges | 4,100 | $ 10,000 | ||
Other associated restructuring costs | 2,000 | |||
Accelerated depreciation | 1,000 | |||
Cash payments | 7,000 | 300 | ||
Ending restructuring accrual | 8,800 | 9,700 | $ 8,800 | |
Restructuring expense | 7,134 | 10,003 | 17,137 | |
2023 Plan [Member] | Operating Segment [Member] | Nu Skin [Member] | ||||
Restructuring [Abstract] | ||||
Restructuring expense | 5,661 | 5,356 | 11,017 | |
2023 Plan [Member] | Operating Segment [Member] | Americas [Member] | ||||
Restructuring [Abstract] | ||||
Restructuring expense | 3,145 | 598 | 3,743 | |
2023 Plan [Member] | Operating Segment [Member] | Mainland China [Member] | ||||
Restructuring [Abstract] | ||||
Restructuring expense | 1,017 | 2,910 | 3,927 | |
2023 Plan [Member] | Operating Segment [Member] | Southeast Asia/Pacific [Member] | ||||
Restructuring [Abstract] | ||||
Restructuring expense | 307 | 862 | 1,169 | |
2023 Plan [Member] | Operating Segment [Member] | Japan [Member] | ||||
Restructuring [Abstract] | ||||
Restructuring expense | 24 | 0 | 24 | |
2023 Plan [Member] | Operating Segment [Member] | Europe & Africa [Member] | ||||
Restructuring [Abstract] | ||||
Restructuring expense | 677 | 554 | 1,231 | |
2023 Plan [Member] | Operating Segment [Member] | South Korea [Member] | ||||
Restructuring [Abstract] | ||||
Restructuring expense | 134 | 0 | 134 | |
2023 Plan [Member] | Operating Segment [Member] | Hong Kong/Taiwan [Member] | ||||
Restructuring [Abstract] | ||||
Restructuring expense | 357 | 432 | 789 | |
2023 Plan [Member] | Operating Segment [Member] | Rhyz Investments [Member] | ||||
Restructuring [Abstract] | ||||
Restructuring expense | 0 | 0 | 0 | |
2023 Plan [Member] | Operating Segment [Member] | Manufacturing [Member] | ||||
Restructuring [Abstract] | ||||
Restructuring expense | 0 | 0 | 0 | |
2023 Plan [Member] | Operating Segment [Member] | Rhyz Other [Member] | ||||
Restructuring [Abstract] | ||||
Restructuring expense | 0 | 0 | 0 | |
2023 Plan [Member] | Corporate and Other [Member] | ||||
Restructuring [Abstract] | ||||
Restructuring expense | $ 1,473 | 4,647 | $ 6,120 | |
2023 Plan [Member] | Minimum [Member] | ||||
Restructuring [Abstract] | ||||
Estimated total charges under restructuring program | 20,000 | |||
2023 Plan [Member] | Maximum [Member] | ||||
Restructuring [Abstract] | ||||
Estimated total charges under restructuring program | $ 25,000 |
MM"T_Z&/1$)M#UPM-3]*+%6#@N6;8QY(A!D,[=$*_SZV'7!#Z5NAU6,]:N[/6
M;N+L"]8JI^OG.U(4@"_:!U1GJOM^8X_=+_$@?$>W*,77,YZ8%-=[/%O^^ /T
MS)]5LW%*L6A*L7A*L61*L?5$8KV<<;J<<4:GX^^\UGE=\&7FBB_@*2FQ*D..
M$NY9NIK2?-,2D9:(M40R)""T?4^:7#JJYY/;^>2.^G1 6.L.0P [EX+P-P6G]>!Z]>G%V/)U<1#_3
MBC(Q%E[O^ (QUPSAD]SZK/)[?4W'^A14;!\*I8EM-Q,5V8L=\$D+'LCVA:Y#
M)$/R?T=G/Q3;3J!(>9!$H?8<4I1Y% B
MF0\;JK5& =/X?4$L#
M!!0 ( '.CJ%@T6=P?1P0 * , 9 >&PO=V]R:W-H965T 9&UZY23;+)J 3
MW*3B)LL2\IM;N0*DI%QH4)SJ1).WZPHK$KQRR]4;.)_%TT%RRHT ::B4LE4-
MOY=8HXA,:*H%F(0*-/U=6(164;WR&_$=O]#9[J&%CS>-D@OXS.COJCZ=E.(-YAI\SGR.MZ")W^
M_V(QF_3/QL<'8E&__-]C<7QZMGO[QV,!#\W&S<\?CL7KX_YT-(K>;"^::+0F
MUDP0G]/^R8SC
C'W4)<[.V038O-
M#IC^3:V*;JWZFO3)<$M+512AQ#,/@9SYARPJ)L5FU+["Q0CY=H3)P54(D2',
MIP6WB3)K9B\;3?O3DVDT[I^=G48X0>W -CVAF[,SSN*I.!3!\[_;?_&!'/C+
M_->F3+@\GN'R[A#30VS:3#R;1O=R$RK# XOFS;/NWI8=.$S0/MZ(0\E_ON\$
M]:D[AV(3Y8W4^B[@)^'M0EC4;L<\AX$ CQ'U:8BG-HS;%>8U\\T<+#.,OD5H
M!8AM;-0 <7T'^^;)WXIW$KI,PG#$9E7=*UO3-@MZLS ^<7KUZF%";[
M.E8,Z=YC&%69HS]"'>1N:LT?#":$N:EY8)4Y2H$&8\G#0KN%[JVHK;YQOJ;A
M"3303( ZW>55UWQIXD^WTV'JIIQ\&LG<5;$G$>U?V)H1@RL[T)C+FF$Q3Q/I
M$2,A65)6I]M[Y6 2Q]BHC0XFH
63R!)U<^Z=[COL"CM[^']R'.55ER;9R!ME"- 6^8=^AKH878
M&0(PM/"LZ&6A?[EXMSO[BE#\U1?9WQI\_PV2_J826H(GT!C-R0R/,0FFLQ3N
M-)A&"?H,,V;I@G!;0 QADR44$Q:0&<$D#A+&T#W,G05$VN(;(_GDCF=R*3-$
M&% $LV@.UWD
[\W9LP#3X.$!SW!,=#Z/-+T;2"
M ]>*B))8NN3S$V:=@E-4!\%.4WVL@!1'7FKK!3HO9 ,2"%6D%#4F*:KAR^AA
M1)8XHE(1QHFNQ%I1OE3OSYS'2@(<73K!*RLJO#/'7)EYQ,X?+4BJ&5\=NWHQ
M7PBEG;=.Z@5IBN_<"]/0^4HE,WH\W!-Z69;B,\@2YXIQR@MX!GW>"*G9O]1F
M.\8H34)^$.6'M3+1*=#*R9+<8 2!<\TU1JTTP